Sources: FTC: challenge to Covetrus acquisition of MWI
The contested transaction
Original analytical illustration; not measured quantities
Sources: [1] FTC: challenge to Covetrus acquisition of MWI · 2026-11-13; allegations in a newly announced court proceeding
The proceeding announced
On November 13, the FTC challenged Covetrus’s proposed $3.5 billion acquisition of MWI Veterinary Supply from Cencora. The agency alleges higher costs and weaker service for veterinary customers. Its complaint, joined by 13 states, begins a contested proceeding. These are allegations, not a judicial finding or a completed prohibition. [1]
The distribution mechanism
A distributor sits between manufacturers and the clinics that need products reliably. Competition can concern delivery, availability, rebates and service as well as the price printed on an individual item. ACTA DIURNA’s interpretation is that the economic question requires examining the package customers actually buy. A list of companies that sell some veterinary products would not, by itself, establish whether they offer a practical substitute for a clinic’s complete procurement requirements. A useful comparison would hold the basket, delivery frequency and payment period constant, then test whether the alternative can supply all three. Otherwise a lower quoted item price can conceal a more costly purchasing process.
A transaction value is not a harm estimate
The announced purchase price describes the deal, not the amount customers would lose or the value of any remedy. Those are separate calculations requiring evidence about prices, volumes, substitution and time. This report does not infer a damages figure from the transaction headline. Nor does the filing establish that every customer faces the same competitive conditions. Independent practices and large purchasing organizations may have different bargaining tools and operational requirements that must be examined on their own evidence.
The procedural stage matters
A challenge changes the transaction’s timetable and introduces litigation risk, but it does not supply the ultimate legal outcome. The parties can contest factual assertions and economic analysis. A reader assessing the business implications should keep the complaint, the companies’ responses and any later court orders distinct. This report relies on the agency’s published announcement for the existence and stated theory of the case; it does not present a private assessment of evidence that has not been reviewed.
Where the commercial uncertainty sits
While a transaction is contested, customers, employees and suppliers may need to plan under more than one ownership outcome. That does not imply that ordinary operations stop. It means that integration decisions, investment priorities and future contractual arrangements may remain contingent. An analyst should identify which actions are reversible and which depend on clearance, rather than treating the entire business as frozen or assuming that the announced combination will necessarily proceed.
The evidence to follow
The useful next material is the court record: the relief requested, the parties’ responses, evidentiary rulings and any decision. Commercial information about customer switching and alternative distribution capacity would help assess the economic mechanism. A settlement, if one is proposed, would require its own examination of scope and implementation. Until then, the defensible description is a contested acquisition challenged by public authorities. This issue does not turn an allegation into a verdict or predict the eventual resolution.
Sources & methodology
Bracketed numbers refer to the sources below. Analysis is original editorial interpretation, not a personalized recommendation.
- FTC: challenge to Covetrus acquisition of MWI · 2026-11-13; allegations in a newly announced court proceeding
